ixazomib
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
Takeda’s Ninlaro extends myeloma survival in trial
December 7, 2015Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma
Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
Clinigen launches UK managed access program for Takeda’s ixazomib
November 30, 2015Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology
Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …
Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
Takeda gets European MAA approval for ixazomib
August 21, 2015Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma
Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …
Takeda cancer drug gets EMA boost
July 29, 2015Research and Development, Sales and Marketing Takeda, ixazomib, multiple myeloma
The EMA has granted Takeda an accelerated assessment for its multiple myeloma drug, ixazomib. The Agency’s Committee for Medicinal Products …
Future bleak for Novartis’ myeloma drug
November 21, 2014Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat
Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …
